

STRENGTHENING PEDIATRIC PHARMACOVIGILANCE: A REVIEW OF BARRIERS AND ENABLERS IN ADVERSE DRUG REACTION REPORTING

Vankar Alpana Jagdish*, Dr. Nidhi Chauhan, Dr. Megha Shah, Mrs. Jimisha Kher,
Patel Disheeta, Khan Kaif

Laxminarayandev College of Pharmacy, Bholav, Bharuch.

Article Received on 15 June 2026,
Article Revised on 05 July 2026,
Article Published on 16 July 2026,
<https://doi.org/10.5281/zenodo.21355971>

*Corresponding Author

Vankar Alpana Jagdish

Laxminarayandev College of
Pharmacy, Bholav, Bharuch.



How to cite this Article: Vankar Alpana Jagdish*, Dr. Nidhi Chauhan, Dr. Megha Shah, Mrs. Jimisha Kher, Patel Disheeta, Khan Kaif. (2026). Strengthening Pediatric Pharmacovigilance: A Review of Barriers And Enablers In Adverse Drug Reaction Reporting. World Journal of Pharmaceutical Research, 15(14), 32–42.

This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Pediatric patients are uniquely susceptible to adverse drug reactions (ADRs), yet pharmacovigilance systems often fall short in capturing these events adequately. A key barrier is underreporting by healthcare professionals, driven by a complex interplay of educational, institutional, and perceptual factors. This review builds upon the central findings of the study “Adverse drug reaction reporting in paediatrics: understanding and contributing factors,” examining systemic challenges and integrating evidence from complementary literature to propose actionable strategies for enhancing ADR surveillance in children. We highlight educational gaps, reporting hesitancy, workflow constraints, and suggest innovations such as structured training, digital reporting platforms, and the use of validated tools to promote safer pediatric pharmacotherapy. Pediatric adverse drug reactions

(ADRs) remain a serious but underappreciated public health issue. Drawing from seven global studies and contemporary advancements in artificial intelligence (AI), this review offers a unique synthesis of empirical data and future-oriented solutions.

1. INTRODUCTION

Adverse Drug Reactions (ADRs) are defined by the World Health Organization (WHO) as "a response to a drug that is noxious and unintended and occurs at doses normally used in humans for prophylaxis, diagnosis, therapy of disease, or for the modification of

physiological function." ADRs in pediatric populations present unique challenges due to differences in physiology, pharmacokinetics, and pharmacodynamics compared to adults. Children, especially neonates and infants, are more vulnerable to drug-related harm due to immature organ systems and metabolic pathways.

ADRs in children are a significant cause of morbidity and can even lead to mortality. Studies have shown that the incidence of ADRs in hospitalized children ranges from 0.6% to 16.8%, while fatal ADRs are reported in about 0.01% to 0.1%. The rate is particularly high in neonatal and pediatric intensive care units due to the use of multiple medications and critically ill status.

Common Types of ADRs in Pediatrics

1. Type A (Augmented): Predictable and dose-dependent (e.g., hypoglycemia with insulin).
2. Type B (Bizarre): Unpredictable and not dose-dependent (e.g., anaphylaxis with penicillin).
3. Type C (Chronic): Related to long-term use (e.g., growth suppression with corticosteroids).
4. Type D (Delayed): Appears after a prolonged time (e.g., secondary cancers after chemotherapy).
5. Type E (End-of-use): Occurs on drug withdrawal (e.g., withdrawal seizures after stopping antiepileptics).
6. Type F (Failure): Ineffectiveness of the drug (e.g., due to drug resistance or poor absorption).

❖ PHARMACOVIGILANCE

Pharmacovigilance (PV) is the systematic process of detecting, assessing, understanding, and preventing adverse drug reactions (ADRs) and other drug-related problems. It plays an important role in ensuring that medicines remain safe and effective after they are marketed and used by the general population. According to the World Health Organization (WHO), pharmacovigilance is the science and practice concerned with identifying and preventing adverse effects associated with medicines.

Pharmacovigilance is not limited to conventional drugs; it also covers vaccines, biological products, herbal medicines, blood products, and medical devices. The importance of pharmacovigilance became evident after the thalidomide tragedy in the 1960s, which led to

the establishment of the WHO International Drug Monitoring Programme, coordinated by the Uppsala Monitoring Centre in Sweden.

Nursing officers handled the highest number of adverse drug reaction cases, followed by senior nursing officers, whereas very few cases were managed by higher nursing authorities. Among the nurses who had cared for patients with adverse drug reactions, only some reported the cases, while others did not. The main reasons for not reporting included considering the reaction as a normal drug effect, lack of awareness about reporting requirements, poor understanding of the reporting process, and unavailability of reporting forms.

- **Importance of Pharmacovigilance**

- 1. Patient Safety**

- Helps in identifying unknown adverse effects

- Detects safety issues at an early stage

- Promotes rational and safe use of medicines.

- 2. Public Health**

- Prevents large-scale drug-related harm

- Supports evidence-based healthcare decisions

- Protects vulnerable populations such as children and pregnant women.

- 3. Drug Risk Monitoring**

- Helps update drug warnings and safety information


- Maintains the benefit–risk balance of medicines

- Supports regulatory and clinical decisions.

Nursing officers handled the highest number of adverse drug reaction cases, followed by senior nursing officers, whereas very few cases were managed by higher nursing authorities. Among the nurses who had cared for patients with adverse drug reactions, only some reported the cases, while others did not. The main reasons for not reporting included considering the reaction as a normal drug effect, lack of awareness about reporting requirements, poor understanding of the reporting process, and unavailability of reporting forms.

2. Unique Risks of Pediatric ADRs

- Pediatric populations face increased risks due to:
 - Off-label or unlicensed drug use:
 - Off-label drug use means using a medicine in a way that is not officially approved. This could be:
 - For a different illness
 - In a different age group (like children)
 - At a different dose or method (like injection instead of tablet)
 - It is legal and common but should be based on medical judgment and evidence.
 - Human error in ADR risk refers to mistakes by healthcare providers or caregivers that can lead to adverse drug reactions (ADRs). These errors include:
 - Wrong drug or dose
 - Misreading labels or instructions
 - Incomplete patient history (e.g., allergies)
 - Lack of monitoring or follow-up
 - Such errors increase the risk of harm, especially in children, where dosing is more sensitive. Proper training, double-checking, and using electronic systems can reduce these risks.
 - Age-dependent drug handling means that a child's body processes medicine differently at each stage of growth.
 - Babies may absorb, break down, and remove drugs slower due to immature organs.
 - Older children process drugs faster as their liver and kidneys develop.
 - Because of this, doses must be carefully adjusted by age to avoid side effects or treatment failure.
 - Studies show that a large proportion of ADRs in children are preventable, especially in outpatient settings (Taché et al., 2011), underscoring the importance of timely and accurate reporting.



Challenges and Ethics in Pediatric AI Deployment

Privacy: Strong data protections required under GDPR/HIPAA.

Bias and Representation: AI must be trained on diverse, pediatric-specific datasets.

Explainability: Clinicians must understand and trust AI insights.

Consent: Pediatric AI must involve parents in transparent decision-making.

3. METHODOLOGY

Building on the findings of Ulfvarson *et al.* (2018), common barriers include:

3.1 Knowledge Deficits

Many clinicians lack training in identifying and reporting ADRs, especially those specific to pediatric care. For example, QUESA-P data (Tavares *et al.*, 2019) demonstrated a significant knowledge gap among pediatric care providers. QUESA-P is a structured questionnaire designed to improve the reporting of adverse drug reactions (ADRs) in children. It helps collect clear and complete information on side effects, including the child's symptoms, drug details, timing, and outcomes. By making it easier for caregivers and healthcare providers to describe what happened, QUESA-P enhances the quality of pediatric ADR data and supports better drug safety monitoring.

Here are the steps of using QUESA-P in short form

1. Detect ADR – Suspected side effect in a child is identified.
2. Start QUESA-P – Questionnaire is initiated.
3. Collect Data – Record drug, symptoms, timing, outcome, etc.
4. Review Info – Healthcare provider checks accuracy.
5. Assess Causality – (Optional) Evaluate if the drug caused the ADR.

6. Report – Submit to the pharmacovigilance system.

3.2 Systemic and Institutional Barriers

Healthcare systems often lack streamlined protocols for ADR reporting. Absence of user-friendly digital tools, ambiguity about roles, and inadequate feedback mechanisms all discourage reporting. Overall, the top three barriers to ADR monitoring and reporting were uncertainty about whether the suspected drug caused the adverse reaction (49.3%), shortage of staff (38.8%), and inadequate time for ADR monitoring and reporting (32.2%). These were also the top three barriers reported in community hospitals. In general hospitals, uncertainty about whether the suspected drugs caused the adverse reaction (46.8%) was the most frequently reported barrier to ADR monitoring and reporting. In tertiary care and university hospitals, shortage of staff (61.8%) was the most frequently reported barrier to ADR monitoring and reporting.

3.3 Cultural and Psychological Deterrents

Fear of blame, legal consequences, or reputational harm can inhibit reporting. This is compounded by uncertainty regarding the causality of symptoms in pediatric patients, especially in complex or multi-drug cases. Heavy workload and time constraints shift focus to patient care over ADR reporting.


Fear of blame or punishment discourages reporting.

Non-mandatory systems and poor coordination cause underreporting.

Delayed signal detection and communication affect ADR reporting.

3.4 Time Constraints and Workflow Disruption

Busy clinical environments often lead to deprioritization of ADR reporting, viewed as a low-yield administrative task.



4. DISCUSSION


4.1 Lessons from Comparative Studies

Blake et al. (2014) revealed that pediatric ADRs reported to EudraVigilance were more often vaccine-related and concentrated around a smaller set of drugs and symptoms than adult reports. This specificity should enable more targeted training and monitoring efforts. Additionally, Kopciuch et al. (2019) emphasized the lack of pharmacovigilance preparedness even among pharmacists, a group expected to lead in medication safety initiatives.

Pediatric Adverse Drug Reactions (ADRs): Global Insights and Pharmacovigilance Strategies

A Multi-Country Review of ADR Trends, Risk Factors and Reporting Tools

Study / Tool	Country / Origin	Key Findings	Drug Classes / Focus	Implications for PV
Priyadharsini et al. (2011)	India	60% ADRs linked in infants	Antibiotics	Underreporting in infants, early-risk
Khan et. (2021)	Turkey	69% ADRs linked to vancomycin	NSAIDs, Anti-infectives, Antileptics	Highlights into importance tracking severity premedality
Smyth et al. (2012)	UK	NSAIDs, Anti-infectives	Age-adjusted risk models and reporting tools	Advocate outnnaor-ing for PVingllg
Rieder (2019)	Canada	Off-label use <5 yrs	Camidrtigd foreficrbing surveillance tools	Advocated to need for professional education in PV
Taché et al (2011)	Multi-country	16.5% preventable 52.9% missed in AC	CV drugs, CNS agents	Implementaneasur-able HCP mowid lag
Kopciuch et al. (2019)	Poland	Enables measur-able HCP knowledgicos	highlights enables professional educationIPV	Imblightin 1nfour of professional education
EudraVigilance Database	Europe-wide	Only <11% of ADRs involved children	Vaccines	First framework to close feedback loop
QUESA-P + EudraVigilance	Cross-national	A integrat-onceview or ardata	System-level	First framework loop between education



COMPRATIVE STUDY

5. Strategies to Improve Pediatric ADR Reporting

5.1 Targeted Education and Training

Mandatory pharmacovigilance curricula for clinicians and pharmacists with pediatric-specific modules can address knowledge gaps.

5.2 Simplified and Digital Reporting Systems

Embedding ADR prompts into electronic health records and mobile reporting apps can streamline submission and increase uptake.

5.3 Use of Assessment Tools

Tools like QUESA-P can be adopted for baseline and ongoing assessment of ADR reporting competencies within pediatric units.

5.4 Cultural Change and Non-Punitive Reporting Environments

Fostering a culture of safety over blame, supported by feedback loops and recognition, can motivate professionals to report ADRs more consistently.

6. Bridging the Gap: A Hybrid Model

We propose a three-layered strategy:

1. Foundational Surveillance: Expand active monitoring in high-risk wards (e.g., surgery, oncology).
2. AI-Enhanced Risk Prediction: Use AI to augment—not replace—clinical judgment.
3. Policy and Education: Integrate pharmacovigilance into pediatric training and incentivise reporting.

7. FUTURE DIRECTIONS

Integrating artificial intelligence and machine learning algorithms with real-time pharmacovigilance platforms may allow proactive identification of ADR patterns in pediatric populations. Moreover, national and international collaboration in pharmacovigilance networks should prioritize pediatric data harmonization.

8. RESULTS

This review synthesized findings from seven global studies and relevant literature on pediatric adverse drug reaction (ADR) reporting. The key results are categorized into four primary domains:

❖ Underreporting Remains a Major Barrier

Across all reviewed studies, underreporting was a consistent challenge.

Reporting rates among healthcare professionals ranged from 10% to 35%, with pediatric cases even less frequently submitted. Fear of legal consequences, diagnostic uncertainty, and lack of feedback discouraged clinicians from reporting suspected ADRs in children.

❖ Educational Gaps Persist Among Healthcare Providers

The QUESA-P study (Tavares et al., 2019) identified significant knowledge deficits among pediatricians, nurses, and pharmacists regarding ADR recognition and reporting protocols.

Few training programs included pediatric pharmacovigilance as a mandatory component of clinical education.

❖ Systemic and Institutional Constraints

Studies found that hospitals lacked streamlined reporting protocols and digital infrastructure. Even when electronic systems were available, users cited poor integration with clinical workflows and time constraints as reasons for non-use.

9. CONCLUSION

Adverse drug reaction reporting in pediatrics remains an underutilized yet critical component of drug safety. Barriers rooted in knowledge, culture, and systems can be mitigated through structured training, supportive infrastructure, and the use of evidence-based tools. Anchored by the findings of Ulfvarson et al., this review advocates for an inclusive and proactive approach to pharmacovigilance that prioritizes the unique needs of children. From chloramphenicol-induced gray baby syndrome to AI-predicted opioid toxicity, pediatric ADRs demand both clinical wisdom and digital innovation. By synthesizing global evidence with intelligent technologies, we can reimagine pharmacovigilance—not as a reactive process but as a proactive shield. The future of pediatric drug safety lies at the intersection of vigilance and vision.

10. REFERENCE

1. Ditttrich, A. T. M., Kroeze, Y., Willemsen, M. A. A. P., Draaisma, J. T. M., van Puijenbroek, E. P., & de Loo, D. M. Uncovering the Hidden Hurdles: Exploring Challenges in Pediatric Pharmacovigilance in the Netherlands. *Drug Safety*, 2025; 49(2): 109–118. <https://doi.org/10.1007/s40264-025-01593-y>

2. World Health Organisation. The use of the WHO-UMC system for standardised case causality assessment, 2013; (08.02.2022).
3. https://cdn.who.int/media/docs/defaultsource/medicines/pharmacovigilance/whocausalityassessment.pdf?sfvrsn=5d8130bb_2&download=true.
4. Edwards, I. R., & Aronson, J. K. Adverse drug reactions: definitions, diagnosis, and management. *The Lancet*, 2000; 1255–1259.
5. Aditi T., Abhash Kumar, Deep D. " Adverse Drug Reaction Reporting Patterns in Indian Healthcare Settings: A Meta-Analysis of Barriers and Facilitators " *JAAFR.*, 2025; 974-987.
6. Tawiah Adu-Gyamf, P. K., Mensah, K. B., Ocansey, J., Moomin, A., Danso, B. O., Agyapong, F., & Arthur-Mensah Jnr, R., "Assessment of knowledge, practices, and barriers to pharmacovigilance among nurses at a teaching hospital, Ghana: a cross-sectional study"*Adu -Gyamf et al. BMC Nursing*, 2022; 2-9.
7. Black C, Tagiyeva-Milne N, Helms P, Moir D. "Pharmacovigilance in children: detecting adverse drug reactions in routine electronic healthcare records. A systematic review" *BJCP.*, 2015; 844–854.
8. Simon C., Christopher G., Danya F V., "Ethics of artificial intelligence in prenatal and pediatric genomic medicine", *Journal of community genetics*, 2024; 15-24.
9. Tavares SS, Cruz LN, Castro J, Lopes LC. "Development and validation of a questionnaire for the assessment of the knowledge, management and reporting ADR in paediatrics by healthcare teams (QUESA-P)" *BMJ Open*, 2019; 1-9.
10. Jaremsiripornkul N, Kayrash S, Homkett P, Srisuriyachanchai W. "A nationwide survey of methods and barriers to adverse drug reaction monitoring and reporting among hospital pharmacists in Thailand" *IJPP.*, 2023; 625–632.
11. Aditi T., Abhash Kumar, Deep D. " Adverse Drug Reaction Reporting Patterns in Indian Healthcare Settings: A Meta-Analysis of Barriers and Facilitators " *JAAFR.*, 2025; 974-987.
12. Priyadharsini, R., Surendiran, A., Adithan, C., Sangeetha, G., & Ponnusankar, S. "A study of adverse drug reactions in pediatric patients" *Journal of Pharmacology & Pharmacotherapeutics*, 2011; 277–280.
13. Khan Z, Karataş YF, Güngör O. "Evaluation of adverse drug reactions in paediatric patients: A retrospective study in Turkish hospital" *Frontiers in Pharmacology*, 2021; 1-9.

14. Smyth RM, Gargon E, Kirkham J, et al. “Adverse drug reactions in children—a systematic review” *PLoS ONE*, 2012; 24-61.
15. Rieder MJ “Adverse drug reactions in children: pediatric pharmacovigilance” *CMAJ*, 2019; E770–E771.
16. Taché, S. V., Sönnichsen, A., & Ashcroft, D. M. “Prevalence of adverse drug events in ambulatory care: A systematic review”, *The Annals of Pharmacotherapy*, 2011; 977–989.
17. Kopciuch D, Zaprutko T, Paczkowska A, et al. “Safety of medicines – knowledge, attitudes and practice of pharmacists regarding pharmacovigilance in Poland” *IJERPH*, 2019; 1622- 4583.
18. Blake KV, Saint-Raymond A, Zaccaria C, Domergue F, Pelle B, Slattery J. “Adverse drug reactions in children: a comparison of pediatric and adult reports in the FudraVigilance database” *Drug Safety*, 2014; 795–802.
19. Harpaz et al., Harpaz R, et al. “Performance of pharmacovigilance signal-detection algorithms” *Clinical Pharmacology & Therapeutics*, 2012; 1010-1021.
20. European Medicines Agency. Pediatric pharmacovigilance [Internet]. Amsterdam: European Medicines Agency, 2023. <https://www.ema.europa.eu/en/human-regulatory/post-authorisation/pharmacovigilance/pediatric-pharmacovigilance>
21. Clavenna A, Bonati M. Adverse drug reactions in childhood: A review of prospective studies and safety alerts. *Arch Dis Child*, 2009; 94: 724-8.
22. Napoleone, E. “Children and ADRs (adverse drug reactions)” *Italian Journal of Paediatrics*, 2010; 2-5. (FUTURE DIRECTION).